An Approach Towards Safe and Effective Extended 14 and 21-Day Dosing with rFIX-FP in Hemophilia B

Time: 2:05 pm
day: Day One


• Extended dosing with rFIX-FP should be based upon an individual’s pharmacokinetic and clinical response- Allowing an adequate observation period during an extended dosing trial is key to establish safety and effectiveness
• Following a clear and strategic dosing strategy, safe and effective extended dosing in hemophilia B patients is possible